Pigment Epithelial Detachment
6
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
1 terminated out of 6 trials
80.0%
-6.5% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Aflibercept in Patients With Pigment Epithelial Detachments (PED)
Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
Lucentis to Treat Pigment Epithelial Detachment